Mammalian target of rapamycin complex 1 (mTORC1) is a key regulator of cell metabolism and lymphocyte proliferation. It is inhibited by the tuberous sclerosis complex (TSC), a heterodimer of TSC1 and TSC2. Deletion of either gene results in robust activation of mTORC1. Mature B cells reside in the spleen at two major anatomical locations, the marginal zone (MZ) and follicles. The MZ constitutes the first line of humoral response against blood-borne pathogens and undergoes atrophy in chronic inflammation. In previous work, we showed that mice deleted for TSC1 in their B cells (TSC1 BKO . A higher cathepsin activity, particularly of cathepsin B, was observed, which was reduced by mTORC1 inhibition with rapamycin in vivo. Remarkably, in vivo administration of a pan-cathepsin inhibitor restored LTbR expression, LTa mRNA levels and the MZ architecture. Our data identify a novel connection, although not elucidated at the molecular level, between mTORC1 and cathepsin activity in a manner relevant to MZ dynamics.
Summary
Mammalian target of rapamycin complex 1 (mTORC1) is a key regulator of cell metabolism and lymphocyte proliferation. It is inhibited by the tuberous sclerosis complex (TSC), a heterodimer of TSC1 and TSC2. Deletion of either gene results in robust activation of mTORC1. Mature B cells reside in the spleen at two major anatomical locations, the marginal zone (MZ) and follicles. The MZ constitutes the first line of humoral response against blood-borne pathogens and undergoes atrophy in chronic inflammation. In previous work, we showed that mice deleted for TSC1 in their B cells (TSC1 BKO ) have almost no MZ B cells, whereas follicular B cells are minimally affected. To explore potential underlying mechanisms for MZ B-cell loss, we have analysed the spleen MZ architecture of TSC1 BKO mice and found it to be severely impaired. Examination of lymphotoxins (LTa and LTb) and lymphotoxin receptor (LTbR) expression indicated that LTbR levels in spleen stroma were reduced by TSC1 deletion in the B cells. Furthermore, LTa transcripts in B cells were reduced. Because LTbR is sensitive to proteolysis, we analysed cathepsin activity in TSC1
Introduction
Marginal zone B cells (MZBs) bridge the innate and adaptive immune response. This innate-like activity is achieved by their ability to quickly respond to B-cell receptor and toll-like receptor stimulations by rapid proliferation and secretion of antibodies, primarily of the IgM isotype. This humoral response is critical to protect against a large variety of pathogens until the germinal centre reaction develops. Furthermore, MZB-derived antibodies contribute to the natural antibody pool. The marginal zone (MZ) itself is strategically located at the interphase with the bloodstream, allowing their proximity to blood-borne antigens. For efficient activation of MZBs, antigens need to be captured and handed over for stimulation. Hence, many cell types and different capturing mechanisms participate in organizing the MZ architecture in a manner compatible for the execution of MZB activation. 1 Human MZBs are located in the spleen and in lymph nodes, but MZBs in the mouse are located only in the spleen. Because the MZ in the mouse harbours specific types of cells, it can be discerned by a typical immunohistological analysis. The MZ is delineated by a ring of marginal metallophilic macrophages that express Siglec-1 (identified by the MOMA-1 monoclonal antibody, often called the MOMA-1 protein). This layer of cells is physically touching the marginal sinuses, which express the mucosal vascular addressin cell adhesion molecule 1 (MAdCAM-1) adhesion molecule. 2 At the outskirts of the MZ sinuses are the MZ macrophages, which express the macrophage scavenger receptor with a collagenous structure, termed MARCO. 3 All these markers generate ringlike appearances in an intact MZ.
Marginal zone B cells are motile cells, which patrol the follicle area of the spleen and return to the MZ. Retrieval signals such as sphingosine-1-phosphate (S1P), released from the MZ sinusoids and captured by its cognate receptors of MZBs (S1P1 and S1P3), together with integrin/adhesion molecule interactions with the MZ stroma cells ensure the return of MZBs to their original location. Hence, perturbations in homing signals of MZBs result in their specific loss, whereas the follicular B cells that constitute the vast majority of splenic B cells remain intact. 4 Importantly, in the absence of B cells, the MZ does not exist, suggesting that cross-communication with MZ stromal cells is critical to establish this compartment. 5 This is especially intriguing in light of the fact that normal MZ architecture can be maintained in the complete absence of MZBs, as evidenced by various animal models. 6 Several studies addressed the B-cell-specific mechanisms required for MZ formation. For instance, B-cell-specific deletion of interleukin-7 or deletion of components of lymphotoxin signalling lead to the loss of MZBs and the disappearance of the MZ. 7, 8 Whether this is a result of lack of MZ formation or impaired maintenance is not known. Moreover, the factors downstream of the signalling cascades that control MZ have not been documented.
The mammalian target of rapamycin (mTOR) is an evolutionarily conserved serine/threonine kinase, present in two cellular complexes that determine its substrate specificity, mTOR-complex 1 (mTORC1) and mTORC2. 9 mTORC1 plays a major role in cellular metabolism by optimizing anabolic activities to cellular energy and oxygen levels, nutrient availability and exposure to various extracellular stimuli. mTORC1 is regulated by various mechanisms, a potent one is its inhibition by the tuberous sclerosis complex (TSC). Deletion of either TSC component, TSC1 or TSC2, renders mTORC1 hyperactive and less sensitive to stressful signals. Most of the studies that investigated the role of mTORC1 in B cells used loss of function strategies, such as rapamycin, 10 expression of hypomorphic mTOR 11 or conditional deletion of raptor. 12 However, a full understanding of the role of mTORC1 in B-cell development and function requires also a gain-of-function approach. We have generated mice in which TSC1 was conditionally deleted in B cells (referred to as TSC1 BKO ). These mice exhibited a severe loss in MZBs and accordingly responded poorly to challenges with a T-independent antigen. 13 An independent parallel study that analysed the same mouse model confirmed these observations. 14 We report that the lack of MZBs in TSC1 BKO mice is accompanied by an abnormal MZ architecture and impaired MZ function. Expression of lymphotoxin a (LTa), but not LTb, was reduced in TSC1 knockout (KO) B cells and was elevated by rapamycin treatment. The surface expression of the lymphotoxin receptor, LTbR, was also reduced in the splenic stroma, implicating shedding as a potential mechanism. In support, we found an elevated cathepsin activity in the TSC1 KO B cells that was reduced by rapamycin treatment. Remarkably, in vivo inhibition of cathepsins restored MZ architecture, elevated LTbR expression in the spleen and corrected the reduced LTa expression in B cells. This study underscores for the first time the cathepsin proteases as key players in the maintenance of MZ architecture and their regulation by mTOR.
Materials and methods

Mice
CD19-Cre/TSC1
f/f and the CD19-Cre mice were previously described. 13 To generate mice in which B cells are fluorescently labelled, we crossed the mice with the ROSA26 LSL-YFP , as described in ref. 15 . The resultant strains CD19-Cre/TSC1 f/f /YFP and CD19-Cre/YFP were used for the transfer experiments of B cells into JHT mice, lacking B cells. The RERT strain was provided by Dr Mariano Barbacid (CNIO, Madrid, Spain).
Immunohistochemistry
Spleens were immersed in 4% paraformaldehyde for 2 hr at 4°; then, transferred to a 30% sucrose solution for overnight incubation at room temperature. Following freezing in OCT (Scigen, Gardena, CA, USA, Cat#4583) at À80°, 5-to 7-lm-thick sections were prepared on a Leica CM1950 cryostat. Tissue sections were washed twice with PBS-T (phosphate-buffered saline with 0Á1% 
Uptake of bioparticles by MZ macrophages
Two hundred micrograms of heat killed Alexa Flour 488-conjugated Staphylococcus aureus bioparticle (Invitrogen, Carlsbad, CA; Cat# S23371) were injected into the tail vein of mice. Mice were killed 30 min later and splenocytes were isolated. Splenocytes were stained for MARCO using Rat PE-MARCO antibody (BioRad, Hercules, CA; MCA 1849PE) and analysed by flow cytometry.
MZ formation assay
B cells were isolated from the spleen using the EasySep Mouse B-cell enrichment kit (STEMCELL, Vancouver, Canada); 20 9 10 6 splenic B cells were injected into the tail vain of JHT mice at day 1 and day 3. At day 14, mice were killed and spleens were analysed by immunohistochemistry.
Induction of TSC1 deletion in RERT/TSC1
f/f mice Three milligrams of tamoxifen in corn oil (20 mg/ml) were injected twice subcutaneously with a 1-day interval into the remaining animals. Mice were analysed for MZ structure at the indicated time after tamoxifen treatment.
Cathepsin activity labelling
B cells were lysed in RIPA buffer [1% Tergitol-type nonidet P-40, 0Á1% sodium dodecyl sulphate (SDS), 0Á5% sodium deoxycholate] on ice for 10 min, and proteins were quantified by Bradford assay. Equal amounts of total protein extracts (50 lg) in acetate buffer (50 mM acetate, 4 mM dithiothreitol, 5 mM MgCl 2 , pH 5Á5) were labelled with GB123, a fluorescent cathepsin-activity-based probe 16 (1 lM), for 1 hr at 37°. Reaction was stopped by addition of Laemmli reducing sample buffer and boiling of the samples for 5 min. Fluorescently labelled proteins were then separated by 12Á5% SDS-polyacrylamide gel electrophoresis (PAGE) and visualized by Typhoon FLA 9500 scanner at 635/670 nm excitation/emission. The signal intensities of cathepsin B activity band from fluorescent gel scans were quantified using FIJI/IMAGEJ software. The values obtained for cathepsin activity were normalized to those of total protein quantification from Coomassie stained for each sample, which were similarly quantified.
Cathepsin activity measurement in intact cells
One million B cells or two million splenocytes isolated from the spleens of TSC1 KO or wild-type (WT) mice were incubated with 2 lM GB123 in medium for 4 hr at 37°. Excess of unbound probe was removed by centrifugation (100g, 5 min, 4°) and cells were washed for another 1 hr by gentle shaking and replacing the medium every 10 min. Cells were analysed by flow cytometry or used for cytospin preparations. For imaging analysis, cells were resuspended in cold 1% bovine serum/PBS, loaded into cytospin cuvette and centrifuged by a Cytospin 2 centrifuge (ThermoScientific, Shandon, UK) at 100 g for 5 min, followed by cold methanol fixation. Cover slips were mounted on the samples with DAPI Fluoromount-G (Southern Biotech, Birmingham, AL). Fluorescent images were taken with a Nikon LT SMZ25 inverted fluorescence microscope equipped with 60 9 oil objective and Cy5 and DAPI filters.
Rapamycin and GB111-NH 2 in vivo treatment
TSC1
BKO mice were treated with GB111-NH 2 cathepsin inhibitor by intraperitoneal injections (1 mg/mouse in 10% dimethyl sulphoxide, 15% Tween-80, 75% PBS). GB111-NH 2 was administered to mice in two rounds of 3 days, followed by 3 days of saline treatment. Following killing, liver, kidney and spleen were harvested. A third of the spleen was analysed by immunohistochemistry. The remains of the spleen and other organs were frozen in liquid nitrogen. Tissues were lysed using an electric TissueRuptor homogenizer (Qiagen, Hilden, Germany) in RIPA buffer on ice (as described above), and proteins were quantified by Bradford assay. Equal amount of total protein extracts (50 lg) in acetate buffer (50 mM acetate, 4 mM dithiothreitol, 5 mM MgCl 2 , pH 5Á5) were labelled with 1 lM GB123 for 1 hr at 37°, labelling reaction was stopped by adding sample buffer and boiling. Fluorescently labelled proteins were then separated by 12Á5% SDS-PAGE and visualized as described above. Rapamycin was administered in vivo as described in ref. 13 .
Cleavage of LTbR and co-culture experiments
CHO-K1 cells (4Á5 9 10 5 ) transfected with an LTbR-GFP fusion vector (TransIT â -2020 Transfection Reagent, Mirus, Mirus Bio, Madison, WI) were incubated in a 96-well plate in acetate buffer (pH 5Á5) for 3 hr with recombinant cathepsin B or L (1Á67 or 1Á65 lM, respectively) or vehicle control at 37°under gentle shaking. Cells were then lysed directly in sample buffer, boiled for 3 min and equal protein amounts were analysed by Western blotting with anti-GFP antibody. For co-culture experiments, we used the LTbR-GFP transfected CHO cells. One day after transfection, 1 9 10 5 cells were seeded in a six-well plate. The next day, 10 9 10 6 B cells were added on top and cultured for additional 24 hr. Lymphocytes were washed out extensively, and the adherent CHO cells were harvested and lysed in cold RIPA buffer. Lysates were analysed by Western blotting on a 12% SDS-PAGE with anti-GFP.
Quantitative polymerase chain reaction analysis of LTa and LTb
Total RNA was isolated from splenic B cells by Trizol and cDNA was generated using the iScript kit (BioRad) and subjected to quantitative polymerase chain reaction (PCR) analysis using the following primers: LTa-F: CCA CCT CTT GAG GGT GCT TG; LTa-R: CAT GTC GGA GAA AGG CAC GAT; LTb-F: TGG CAG GAG CTA CTT CCC T; LTb-R: TCC AGT CTT TTC TGA GCC TGT; UBC-F: CAG CCG TAT ATC TTC CCA GAC T; UBC-R: CTC AGA GGG ATG CCA GTA ATC TA.
Results
Loss of MZ architecture in TSC1 BKO mice
To examine whether the reduction in MZBs in TSC1 BKO mice is accompanied by histological changes to the MZ architecture, spleens of TSC1 BKO mice were examined for the typical ring structure when stained for the various MZ markers. We observed the dissipation of the typical MZ structures in TSC1 BKO mice. Instead of ring-shaped structures of MOMA-1, MAdCAM-1 and MARCO expressing cells seen in spleens of WT mice, a scattered and punctuated pattern was observed in the TSC1 BKO spleens ( The inhibition of mTORC1 with rapamycin causes an induction of AKT activity, known as the mTOR feedback. 17 Conversely, induction of mTOR activity through the genetic loss of TSC inhibition, typically causes the repression of AKT in a manner that can be circumvented by the co-deletion of phosphatase and tensin homologue (PTEN). Because AKT activity positively regulates the development of MZBs, 18 it raises the possibility that the phenotype seen in the TSC1 BKO (Fig. 1) . We conclude that the factors that control the architecture of the MZ and the loss of MZBs are downstream to the mTORC1 and are not a result of a feedback for the attenuation of AKT activity.
Impaired uptake by MZ macrophages in TSC1 BKO mice
To assess whether the impaired architecture in the TSC1 BKO mice is also associated with impaired function of the MZ, we applied a capturing assay that was used to demonstrate the MZ functional defect in CD19 KO mice. 19 In this assay, mice were challenged with fluorescently labelled (Alexa 488) StaphA, also known as bioparticles. The bioparticles are introduced intravenously and their capturing by splenocytes is analysed within 30-60 min. Cells that engulfed the fluorescent bioparticles are gated, and MARCO expression is measured. For CD19 KO mice, which lack MZBs, this assay demonstrated a 40% reduction in the levels of MARCO among the bioparticle-positive cells compared with WT. 19 To assess the dynamic range of this assay in our hands, we administered the bioparticles to WT and RAG2 KO mice, which lack the adaptive system and have no detectable MZ. The expression of MARCO on the bioparticle-positive cells was lowered by 50%, similar to what was described for the CD19 KO mice (see Supplementary material, Fig. S2 ). When applied to TSC1 BKO mice, an approximately 30% reduction in MARCO expression was observed on the bioparticle-positive cells, confirming a defect in MZ function (Fig. 2) . easily discerned owing to the YFP expression, which was equivalent for both donor mice (Fig. 3a) . Two intravenous inoculations of 20 9 10 6 splenic WT B cells into the B-cell-deficient JHT mice were sufficient to restore the typical MOMA-1 rings (Fig. 3b, top) . The MOMA-1 rings were not observed following the transfer of TSC1 KO B cells, although both B-cell genotypes homed to the spleen at similar efficiency following intravenous transfer (Fig. 3b, bottom) . These data suggest that the lack of TSC1 in the B cells impairs the mechanisms that support the formation of MZ architecture. Induced deletion of TSC1 confers the disintegration of pre-existing MZ
To further explore the possibility that mTOR induction by TSC1 deletion can lead to an active dissipation of MZ architecture, we crossed the floxed TSC1 mice to the RERT strain. The latter strain expresses a CRE-ER fusion knocked into the heavy subunit of the RNA polymerase II subunit. 21 Hence, administration of tamoxifen in vivo to RERT/TSC1 f/f induces the ubiquitous irreversible deletion of TSC1 in all cell types. Performing kinetic analyses revealed that MZ B cells and MZ architecture were maintained 15 days after tamoxifen administration. However, 35 days after the tamoxifen challenge both MZ B cells and the MOMA-1 ring were no longer detected (see Supplementary material, Fig. S3 ).
mTORC1 activity suppresses lymphotoxin expression
Lymphotoxins play a major role in the generation of peripheral lymphoid tissues. Germline deletion of either LTa, LTb or LTbR results in major defects in the generation of peripheral lymph nodes and spleen architecture in mice. 22 MZ development is completely dependent on LT-mediated signals during early organ development, as it is completely distorted in either of the aforementioned lymphotoxin KO mouse strains. Moreover, even a partial reduction in lymphotoxin expression in the B cells is sufficient to distort MZ architecture in the spleen. 23 To our knowledge, most of the commercial reagents for LTbR were not validated for specificity. Following the testing of a few, we present data of immunofluorescence staining of spleen cryosections for LTbR (Abcam, #ab186847), which according to the company is reacting against the antigen in immunohistochemical applications. LTbR is expressed by multiple cell types of the spleen, including dendritic cells and innate lymphoid cells, but not in B or T cells. In WT mice, we observed a punctate pattern of staining with a few cells that stain bright, providing confidence that the antibody indeed identifies LTbR. As expected, there was no overlap of LTbR bright cells with the B cells, providing further credibility to the staining. In TSC1 BKO spleens, these brightly stained cells were not observed. A treatment with rapamycin restored this pattern of staining (we will refer to the panel that shows GB111-NH 2 treatment later; Fig. 4a ). These data suggest that upon mTORC1 activation in B cells, the surface expression of LTbR in the stroma cells is reduced. In addition to this, analysis of LTa and LTb mRNA levels indicated a reduction only in LTa levels in TSC1 KO B cells. This reduction was completely reversed by in vivo rapamycin treatment, connecting the mTORC1 activity to the control of LTa transcripts (Fig. 4b) . 
Cathepsin activity is elevated in TSC1 KO B cells
Although not having the total LTbR KO mice to validate the specificity of the stainings, the data suggest that LTbR may undergo a proteolytic shedding, a phenomenon that has been described for human cells, but has not been reported in mice. 24 Cathepsins are proteases that mainly reside in the lysosomes and have been shown to be involved in several normal and pathological processes. Cathepsins can translocate to the plasma membrane 25 and can also be secreted upon stimulation and following transformation. 26, 27 At first, we assessed the sensitivity of LTbR to cathepsin cleavage. To be able to capture the cell-bound portion of LTbR following cleavage, we tagged the C-terminus of LTbR with GFP and expressed the fusion protein in CHO cells, then exposed the cells to recombinant cathepsin B or L. After 3 hr with the cathepsins, a 45 000 molecular weight fragment of LTbR-GFP was detected, consistent with the cleavage of the entire LTbR ectodomain (see Supplementary material, Fig. S4 ). Both enzymes displayed a similar proteolytic pattern. Next, we tested whether incubation with TSC1 KO B cells can promote the cleavage. CHO cells were transfected with LTbR-GFP and divided into three equal portions. One portion was left untreated, one portion was incubated with WT B cells and one with TSC1 KO B cells. We clearly observed that the co-culturing of the LTbR-GFP-expressing CHO cells with the B cells caused the reduction in the expression levels of the total LTbR-GFP. Nonetheless, the incubation with TSC1 KO B cells, less with WT cells, resulted in the generation of a cleaved intracellular portion of LTbR-GFP (see Supplementary material, Fig. S4 ). This fragment, however, was smaller than was observed with the recombinant cathepsin, implicating additional proteolytic processing promoted by TSC1 KO cells. These data encouraged us to measure cathepsin activity in WT and TSC1 KO B cells using our fluorescently label activity-based probe. Activity-based probes covalently bind and label the active site cysteine residue in a manner that is relative to the protease activity. Hence, epitope-tagged or fluorescently labelled probes enable a direct assessment of the protease activity by SDS-PAGE and detection of the tagged protease. Using the Cy5 activity-based probe GB123, 16 we observed a strong elevation in the activity of cell-associated cathepsin B, but no significant difference for cathepsin L (Fig. 5a) . The same probe can also be used for fluorescence microscopy using cyto-spun cells and flow cytometry. In all assays, deletion of TSC1 conferred a strong increase in the activation of total cathepsin activity (Fig. 5b,c) . It was important for us to test whether the increase in cathepsin B activity in the TSC1 KO B cells is regulated by the mTORC1 activity. We therefore treated TSC1 BKO mice with rapamycin for 1 week, isolated B cells from the spleen and compared cathepsin B activity to vehicle-treated mice. This analysis indicated a significant decrease in cathepsin B activity that was comparable to the difference seen between WT and TSC1 KO B cells (Fig. 6a,b) . We also applied the GB123 labelling method to total splenocytes isolated from WT, TSC1
BKO and rapamycin-treated TSC1 BKO mice. Following labelling, when gating on B cells, we observed a subset of cells that had an enhanced cathepsin activity in the TSC1 KO background. This completely normalized when the mice were treated with rapamycin (Fig. 6c) . Taken together, our data unravel a novel connection between mTORC1 signalling and cathepsin regulation.
The possibility of LTbR shedding is supported by the fact that based on the YFP reporter, the efficiency of KO is not complete. In vivo inhibition of cathepsin activity replenishes MZ architecture in TSC1 BKO mice
In the last set of experiments, we assessed whether inhibition of cathepsins in vivo can restore MZ architecture in TSC1 BKO mice. To this end, we administered GB111-NH 2, 28 a non-fluorescent cathepsin inhibitor, to TSC1 BKO mice for 2 weeks. This dosing regimen was highly efficient in blocking all cathepsin activity in vivo within the spleen as assayed by ex vivo measurements of the residual activity using the fluorescently labelled probe GB123 (Fig. 7a) . Although flow cytometry analyses did not detect the recovery of MZBs (not shown), probably owing to the short duration of treatment, remarkably, analysis of MZ structure revealed intact MOMA-1 rings in the GB111-NH 2 -treated mice as well as intact MAdCAM1 structures (Fig. 7b) . We conclude that systemic inhibition of cathepsin activity suppresses the MZ structure phenotype of TSC1 BKO mice. This was also associated with the elevation of LTa expression (Fig. 7c ) and the appearance of LTbR-positive cells in the spleens of GB111-NH 2 -treated TSC1 BKO mice (Fig. 4a) .
Discussion
The function of the MZBs is regulated by multiple cell types that ensure the position of the cells and their ability to respond to stimulation. This includes at least neutrophils, 29 innate lymphoid type 2 cells, 30 follicular dendritic cells, 31 macrophages and dendritic cells. However, all these interactions are contingent on generating the MZ architecture scaffolds. Because B and T cells constitute the vast majority of the spleen white cells, it is surprising that only B cells are critical to generate the MZ architecture. It is even more surprising that the MZBs, which are able to homeostatically proliferate, are not obligatory for this process. For example, in CD19 KO mice, although MZ macrophage maturation is impaired, the MOMA rings that signify the siglec1-expressing metallophilic macrophage, are normal. 20 A similar phenotype was observed in B cells that over-express BCL3. While MZBs were completely absent, MOMA rings were intact. 6 In this regard, the phenotype of TSC1 BKO is unusual with respect to the distorted MZ architecture (Fig. 1) .
MZBs develop from transitional B cells in a manner that depends on B-cell receptor signalling, nuclear factorjB and Notch2. 32, 33 Although MZBs possess a strong mitogenic response to various stimulations, in vivo and ex vivo, particularly to Toll-like receptor stimulation, whether they undergo in situ homeostatic proliferation is unknown. Bromodeoxyuridine labelling experiment indicate a turnover in the range of 1-2 weeks; however, following this period, half of the bromodeoxyuridinepositive MZBs lingered for a much longer time, suggesting the existence of at least two pools of MZBs with respect to their turnover properties. 34 This illustrates a gap in the understanding of the underlying mechanisms that regulate MZ formation and maintenance, which can be addressed by lineage tracing within the MZB pools, experiments that have not been performed.
We addressed the question of formation and stability of the MZ architecture and observed that the lack of TSC1 is associated with the inability to form de novo MZ structures upon B-cell transfer and also a defect in its maintenance and function (Figs 2 and 3) . These B-cell intrinsic defects that affect the entire architecture of the MZ have been described for only a few molecules, primarily the lymphotoxin family of proteins. While lymphotoxins are expressed by several types of cells within the spleen, 30 the role of lymphotoxins in B cells as critical for MZ formation was documented two decades ago. 35, 36 CD19-Cre-mediated B-cell-specific knockout of LTb is sufficient to confer a pronounced loss of MZ microarchitecture on all its parameters. Remarkably, this striking phenotype was observed notwithstanding a partial efficiency in the deletion. 8 This suggests that a partial compromise in lymphotoxin signalling would be sufficient to confer a similar phenotype. LTbR is expressed in haematopoietic and stromal cells and both are required to mount a protective interferon response against viruses. 37 The reduction in LTbR expression in the spleens of TSC1 BKO was unexpected and suggests communication between the B cells and their environment (Fig. 4) , a result that prompted us to investigate further the possibility of proteolytic shedding.
Cathepsin proteases are mostly found in the lysosome, where the acidic conditions enhance their activity and allow proteolysis. However, cathepsins are not only confined to the lysosome and were shown to leak out to the cytoplasm and nucleus or be secreted following various conditions. 26, 27 We have observed a greater than twofold increase in the mRNA levels of cathepsins L, D and B in TSC1 KO versus WT B cells (not shown), suggesting that in B cells, mTOR activity is connected to expression of several cathepsin genes. However, mRNA levels are not always correlated with proteolytic activity, particularly for zymogens, which require a processing step for activation. We therefore conducted activity assays to establish a positive connection between mTORC1 activity and cathepsin activity in B cells (Figs 5 and 6 ). Interestingly, when we analysed the effect of TSC1 deletion on cathepsin activity in other cell types, such as T cells and bone-marrowderived macrophages, we did not observe significant differences (not shown). Furthermore, a study performed in mouse embryonic fibroblasts and HEK293T cells has shown that the inhibition of mTORC1 by TOR kinase inhibitors, and as a consequence the induction of autophagy, promoted lysosomal functions including that of cathepsin B as measured by fluorescent substrate. 38 This infers the opposite from what we have found for B cells and although in that study the activity of cathepsins was not visualized directly, it suggests a B-cell-specific cross talk between cathepsin activity and mTOR. Indeed, increase in cathepsin expression levels was observed in various types of non-Hodgkin's B-cell lymphomas, such as diffuse large B-cell lymphoma and chromic lymphocytic leukaemia, 39, 40 and is associated with poor prognosis. Whether this is in a correlation with mTOR activity has not been investigated.
Cathepsins, particularly cathepsins B and G, can be secreted or displayed at the cell surface. 25 , 41 We have not been able to detect cathepsin activity released to the medium, when B cells were cultured for 24 hr in the presence of lipopolysaccharide. Whether cathepsins are released in vivo from the TSC1 KO B cells to mediate their action in the MZ environment is plausible, but difficult to directly ascertain. Prolonged treatment with GB111-NH 2 was not tolerated by the mice. We therefore limited the treatment to 1 week, a time frame that may be too short for testing the recovery of the MZBs themselves. For rapamycin treatment, a period of 17 days was needed to see the reappearance of MZBs. 13 However, it was clear that a week-long in vivo treatment with the pan-cathepsin inhibitor was sufficient to restore the MZ architecture in a manner indistinguishable from normal mice (Fig. 7) supported by a possible elevation in LTbR expression (Fig. 4) .
Interestingly, the mRNA levels of LTa were also elevated by the cathepsin inhibitor, connecting the cathepsin to gene transcription (Fig. 7) . Although a connection between cathepsins and gene transcription is mechanistically difficult to imagine owing to the compartmentalization of cathepsin to the lysosomes, multiple studies demonstrate that such connection indeed occurs. Nevertheless, the presence of cathepsins in the nucleus where they can cleave or interfere with the action of transcription factors was reported. 42, 43 Interestingly, a connection between cathepsin B and extracellular-signal regulated kinase (ERK) activity was reported using both inhibitors and knockdown experiments. 44 Because ERK activity promotes the production of lymphotoxins, 45 it is conceivable that this mechanism also operates in B cells to connect cathepsin B and LTa transcription. This possibility is under investigation with ramifications broader than only for lymphotoxin transcription.
The model that emerged from our study suggests that hyper-mTORC1 in the B cells, through yet to be identified actions on cathepsin proteases, leads to global perturbations in MZ architecture, possibly by curtailing lymphotoxin signalling in the microenvironment. An alternative interpretation may be that the TSC1 deletion arrests the B cells in a premature transition state that does not support the generation of the MZ. Several evidences stand against this argument. First, TSC1-deficient B cells yield normal numbers of follicular cells, undergo class switching, and differentiate into plasma cells upon stimulation. [13] [14] [15] Thus, there is no maturation arrest. Second, the fact that incomplete deletion of TSC1, as assessed by the YFP reporter, was sufficient to abrogate MZ architecture, infers a dominant effect of mTORC1. Lastly, other mutations in B cells that block maturation should result in the loss of MZ architecture. Of note, the invariant chain KO mouse strain exhibits a severe block in maturation, almost complete loss of follicular B cells, yet displays normal architecture of the MZ. 46 Together, the data strongly suggest that the observed phenotype relates to the activation of mTORC1 and is not an indirect consequence of an impaired maturation.
The mTOR pathway has been reported to promote cell invasion and metastasis. 47 For several types of malignancies, primarily carcinomas, mTOR activity is higher in metastases than in the primary tumour site and is typically associated with a poorer prognosis. [48] [49] [50] The connection between mTOR and metastatic potential has been mostly attributed to promoting endothelial to mesenchymal transition and allowing the cells to better sustain various stress conditions, such as hypoxia or nutrient starvation. 51, 52 Our study implicates a novel signalling axis between mTOR and proteolytic activity with implications for the microarchitecture of the immune system.
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